News
ALXO
9.57
+0.74%
0.07
ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pon...
GlobeNewswire · 09/21 20:01
ALX Oncology Announces Upcoming Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that managemen...
GlobeNewswire · 09/01 11:00
UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT Newswires · 08/26 10:12
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative™ ("Quantum Leap") today announced that ALX Oncology'...
PR Newswire · 08/16 13:45
ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT Newswires · 08/16 10:37
ALX Oncology And Quantum Leap Healthcare Collaborative Announce The Selection Of Evorpacept In The I-SPY-P1 TRIAL In Combination With Enhertu In Breast Cancer
ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare
Benzinga · 08/15 11:05
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Col...
GlobeNewswire · 08/15 11:00
ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu in Breast Cancer
ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu in Breast Cancer
MT Newswires · 08/15 10:05
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation...
GlobeNewswire · 08/11 11:00
--Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating
--Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating
MT Newswires · 08/09 12:26
--Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating
--Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating
MT Newswires · 08/09 10:07
BRIEF-ALX Oncology Reports Second Quarter 2022 Results
BRIEF-ALX Oncology Reports Second Quarter 2022 Results
Reuters · 08/08 22:39
ALX Oncology GAAP EPS of -$0.81 misses by $0.18
ALX Oncology press release (<span class="tick...
Seekingalpha · 08/08 21:39
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/01 22:41
ALX Oncology Shares Gain As FDA Grants Fast Track Status To Head And Neck Cancer Candidate
ALX Oncology Holdings (NASDAQ: ALXO) receives Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead asset Evorpacept in combination with KEYTRUDA (pembrolizumab) for the first-line treatment of adult patients with PD-L1 posit...
Benzinga · 08/01 12:29
ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
The U.S. Food and Drug Administration (FDA) <a href="https://seekingalpha.com/pr/18885767-alx-oncology-s-evorpacept-receives-fast-track-designation-from-fda-first-line-treatment-for?utm_medium=referral&utm_source=webull.com" target="_blank"...
Seekingalpha · 08/01 11:35
ALX Oncology's Evorpacept Receives Fast Track Designation From FDA As First-Line Treatment For Head And Neck Squamous Cell Carcinoma
ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug
Benzinga · 08/01 11:11
ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. F...
GlobeNewswire · 08/01 11:00
ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).
Benzinga · 06/29 12:53
ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
The U.S. Food and Drug Administration (FDA) grant...
Seekingalpha · 06/29 11:51
More
Webull provides a variety of real-time ALXO stock news. You can receive the latest news about Alx Oncology Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. It is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).